European Medicines Agency launches review of recalled heart drug

The European Medicines Agency (EMA) said Thursday (2 August) it is conducting a review of the health effects on patients of a widely used blood pressure medication recalled around the world last month.

The regulator will analyse the impact of the active ingredient valsartan, produced by Chinese manufacturer Zhejiang Huahai Pharmaceutical Company, after warnings of contamination by a cancer-causing impurity.

The company, listed on the Shanghai stock exchange, launched a global recall of the drug on 18 July following warnings by US and European regulators over the presence of N-nitrosodimethylamine (NDMA), which is believed to potentially cause cancer through long-term use.

In a series of pronouncements last month, Huahai said it had moved to suspend supply and had begun the recall.

Valsartan is a generic drug mainly used for the treatment of high blood pressure and congestive heart failure.

NDMA was an unexpected impurity believed to have formed as a side product after Huahai introduced changes to its manufacturing process in 2012, according to the London-based EMA.

It first issued an alert over the drug on July 5, and American regulators followed up with their own warning a week later.

The EMA repeated Thursday that there was “no immediate risk to patients” and they “should not stop taking their medicines without consulting their doctor or pharmacist”.

The EMA said its review is being carried out by the Committee for Medicinal Products for Human Use, which is responsible for probing concerns over patient medicines.

Its opinion will be forwarded to the European Commission, which will issue a final legally binding decision applicable in all countries in the EU.

Huahai’s stock has dropped more than 20% since the warnings first emerged in early July.

The company could not be reached for immediate comment on Thursday.

EURACTIV's editorial content is independent from the views of our sponsors.

Media is a pillar of democracy – as long as it can function properly. Now more than ever we need unbiased, expert information on how and why the European Union functions. This information should not be behind a paywall, and we remain committed to providing our content for free.

We know our readers value our reporting. We know journalism that covers the EU in a clear, unbiased way is critical to the future of the European Union. And we know your support is critical for ensuring this independent and free journalism.

Don’t take the media sector for granted. It was already fragile before the coronavirus pandemic. And as people can’t meet, media companies have lost a major source of revenue: events. EURACTIV is supported by a mix of revenue streams including sponsorships, online advertising, EU-funded projects, and policy debates. All of these sources of revenue are impacted by the current crisis.

While media struggles, disinformation thrives. We are already seeing fearmongering, fake news about the EU response, and increased threats to freedom of the press.

For more than two decades we have provided free, independent, multilingual reporting on the European Union. We continue to believe in Europe, and we hope you do too.

Your financial support at this critical time will allow our network of newsrooms across Europe to continue their work when Europe needs it most.

Contribute to our reporting

The need for fast, accurate and balanced information is always important. We value EURACTIV's good, independent journalism and support this initiative

Mella Frewen, Director General of FoodDrinkEurope

EURACTIV plays a vital role in bringing Europe closer to its citizens. EURACTIV has long recognised that the story of Europe has to be told across the continent, and not just in Brussels. We need to support a truly European and informed debate.